Weekly Investment Analysts’ Ratings Updates for Veracyte (VCYT)

Several analysts have recently updated their ratings and price targets for Veracyte (NASDAQ: VCYT):

• 12/1/2025 – Veracyte had its price target raised by analysts at Morgan Stanley from $40.00 to $48.00. They now have an “underweight” rating on the stock.
• 12/1/2025 – Veracyte had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Veracyte had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Veracyte had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/16/2025 – Veracyte was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 11/13/2025 – Veracyte had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/11/2025 – Veracyte had its price target raised by analysts at Morgan Stanley from $28.00 to $40.00. They now have an “underweight” rating on the stock.
• 11/8/2025 – Veracyte was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 11/7/2025 – Veracyte was upgraded by analysts at Weiss Ratings from a “sell (d+)” rating to a “hold (c)” rating.
• 11/5/2025 – Veracyte had its price target raised by analysts at UBS Group AG from $42.00 to $48.00. They now have a “buy” rating on the stock.
• 11/5/2025 – Veracyte had its price target raised by analysts at Needham & Company LLC from $41.00 to $44.00. They now have a “buy” rating on the stock.
• 11/5/2025 – Veracyte had its price target raised by analysts at Canaccord Genuity Group Inc. from $40.00 to $43.00. They now have a “hold” rating on the stock.
• 11/5/2025 – Veracyte had its price target raised by analysts at Guggenheim from $40.00 to $45.00. They now have a “buy” rating on the stock.
• 10/20/2025 – Veracyte is now covered by analysts at Canaccord Genuity Group Inc.. They set a “hold” rating and a $40.00 price target on the stock.

Insider Activity at Veracyte

In other news, CFO Rebecca Chambers sold 13,278 shares of Veracyte stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $46.84, for a total value of $621,941.52. Following the sale, the chief financial officer directly owned 109,496 shares in the company, valued at $5,128,792.64. This trade represents a 10.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Annie Mcguire sold 1,422 shares of the business’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $47.30, for a total transaction of $67,260.60. Following the completion of the sale, the senior vice president directly owned 78,499 shares in the company, valued at approximately $3,713,002.70. This represents a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 134,528 shares of company stock valued at $5,896,433 over the last three months. Insiders own 1.40% of the company’s stock.

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.